Method of treating neoplasia with a multimeric IL-15 soluble fusion molecule
US10899821B2 · kind B2 · utility
16Cited by
8References
21Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 11, 2018 |
| Grant date | Jan 26, 2021 |
| Priority date | — |
| Expiry date | Jun 1, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention features compositions and methods featuring ALT-803, a complex of an interleukin-15 (IL-15) superagonist mutant and a dimeric IL-15 receptor α/Fc fusion protein useful for enhancing an immune response against a neoplasia (e.g., multiple myeloma, melanoma, lymphoma) or a viral infection (e.g., human immunodeficiency virus).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.